News and

Curesponse featured in the Marker (in Hebrew)

A new article titled “Targeted response testing that incorporates rapid genomic analysis, for customization of treatment for a cancer patient” was featured in the Israel news outlet, The Marker.

The environment in which a cancerous tumor develops affects the ability of drugs to help eradicate it. Curesponse has developed a method for prioritizing possible treatments, including fast and targeted genomic sequencing and testing the tumor’s response to various treatments. The company hopes to launch soon in Israel.

Want to know more?

Contact Us